Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Receivables (2023 - 2025)

Iovance Biotherapeutics has reported Receivables over the past 3 years, most recently at $82.4 million for Q4 2025.

  • Quarterly results put Receivables at $82.4 million for Q4 2025, up 18.9% from a year ago — trailing twelve months through Dec 2025 was $82.4 million (up 18.9% YoY), and the annual figure for FY2025 was $82.4 million, up 18.9%.
  • Receivables for Q4 2025 was $82.4 million at Iovance Biotherapeutics, up from $66.8 million in the prior quarter.
  • Over the last five years, Receivables for IOVA hit a ceiling of $82.4 million in Q4 2025 and a floor of $33000.0 in Q2 2023.
  • Median Receivables over the past 3 years was $57.9 million (2024), compared with a mean of $43.7 million.
  • Biggest five-year swings in Receivables: skyrocketed 95669.7% in 2024 and later rose 18.9% in 2025.
  • Iovance Biotherapeutics' Receivables stood at $151000.0 in 2023, then soared by 45820.53% to $69.3 million in 2024, then rose by 18.9% to $82.4 million in 2025.
  • The last three reported values for Receivables were $82.4 million (Q4 2025), $66.8 million (Q3 2025), and $59.9 million (Q2 2025) per Business Quant data.